ライフサイエンスコーパス: paresthesia

1 gh novel paradigms provide analgesia without paresthesia.

2 be useful as a model stimulus for studies of paresthesia.

3 tic (e.g. touch or pressure), but were often paresthesias.

4 consistency and intensity, constipation, and paresthesias.

5 man presented with blurred vision and distal paresthesias.

6 nderstood conditions such as hyperpathia and paresthesias.

7 OX4 was associated with more neutropenia and paresthesias.

8 ation was commonly associated with transient paresthesias.

9 r the hands, with a prodrome of pruritus and paresthesias.

10 ropathy (0.9% [three of 320]), and temporary paresthesia (0.9% [three of 320]).

11 ofacial paresthesia (4 events [20%]), finger paresthesia (1 event [5%]), and ataxia (1 event [5%]).

12 Some had paresthesias (17%), elevated CSF protein level (13%), an

13 ection (6%), anemia (5%), weakness (6%), and paresthesia (3%).

14 (25% vs. 12%) in the amitriptyline group and paresthesia (31% vs. 8%) and weight loss (8% vs. 0%) in

15 che (46.8%), fatigue (44.2%), malaise (39%), paresthesias (32.5%), peripheral facial palsy (PFP) (36.

16 ted symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%

17 her persistent adverse events were orofacial paresthesia (4 events [20%]), finger paresthesia (1 even

18 opiramate vs placebo, respectively, included paresthesia (50.8% vs 10.6%), taste perversion (23.0% vs

19 upper respiratory tract infection (7%), and paresthesia (7%).

20 ug infusion and included vasodilation (63%), paresthesia (86%), and somnolence (17%).

21 05), and incidences of peripheral neuropathy/paresthesia and alopecia were significantly higher in pa

22 fects the neural response to SCS relevant to paresthesia and analgesia.

23 lectively increasing SCS frequency abolished paresthesia and epidurally recorded evoked compound acti

24 rtz-frequency SCS produces analgesia without paresthesia and is thought, therefore, not to activate a

25 ts may leave soft tissue scarring, and cause paresthesia and lip droop.

26 dose-limiting toxicities, and side effects (paresthesia and rash) were minor.

27 thy in humans that is accompanied by painful paresthesias and dysesthesias.

28 latin neuropathy is characterized by sensory paresthesias and muscle cramps that are notably exacerba

29 hich began with vomiting and upper extremity paresthesias and progressed to fever, seizures, dysphagi

30 Paresthesias and Raynaud's syndrome (hands and feet) sho

31 difficulties, 4 (9%) a sensation of left arm paresthesia, and 3 (7%) sympathetic flight/fright respon

32 h distal sensory symptoms, such as numbness, paresthesia, and dysesthesias (although the autonomic ma

33 overall risk of NAE, peripheral neuropathy, paresthesia, and dysgeusia was lower with ICI use; howev

34 norexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian an

35 problems including loss of motor control and paresthesia, and generates maladaptive neuroplasticity a

36 ng whether symptoms, such as pain, weakness, paresthesia, and hand dysfunction, are due to the AV acc

37 ve fibers associated with loss of sensation, paresthesia, and persistent pain.

38 arction, leading to upper extremity paresis, paresthesia, and sensory loss.

39 s, including headaches (51%), limb weakness, paresthesia, and/or aphasia (49%), pyramidal syndrome (3

40 rsity with bilateral leg weakness, ascending paresthesias, and decreased sensation.

41 sociated with higher predose anxiety scores, paresthesias, and distinct vital sign and biomarker chan

42 nausea/vomiting, alopecia, thrombocytopenia, paresthesias, and liver function abnormalities.

43 igher disease burden, more stabbing pain and paresthesias, and more anxiety (p < 0.05 for each).

44 ble nausea, renal insufficiency, polydipsia, paresthesias, and myelosuppression.

45 r Scale (UNC4P), which rates pain, pruritus, paresthesias, and pliability.

46 erum creatinine level, insomnia, leg cramps, paresthesias, and tremor, were managed with dose reducti

47 Raynaud's phenomenon as persistent pain and paresthesia are common in the hands and arms and occur i

48 rophysiological underpinnings of SCS-induced paresthesia are unknown.

49 Sensory abnormalities such as numbness and paresthesias are often the earliest symptoms in neuroinf

50 lications assessed included axillary seroma, paresthesia, arm morbidity and range of motion, and lymp

51 nausea) and neurological symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, hea

52 spikes, asynchronous spikes fail to produce paresthesia because their transmission to somatosensory

53 rmation on wound infection, axillary seroma, paresthesia, brachial plexus injury (BPI), and lymphedem

54 ly ash plant family, induces robust tingling paresthesia by activating a subset of somatosensory neur

55 ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysau

56 thy in humans that is accompanied by painful paresthesias, dysesthesias, and occasionally hypoesthesi

57 Symptoms included paresthesias, dysesthesias, cold hypersensitivity, jaw p

58 However, paresthesia evoked by spinal cord stimulation (SCS) at 4

59 ntinuation in the topiramate groups included paresthesia, fatigue, and nausea.

60 m and provide insight into the biophysics of paresthesia generation and pain relief.

61 Paresthesias (hands and feet) and tinnitus showed signif

62 Paresthesias have been considered to be an early effect;

63 ep disturbance, cyanosis, venous dilatation, paresthesia, headache, and tinnitus) in the setting of e

64 ons, thereby contributing to radicular pain, paresthesias, hyperalgesia and allodynia.

65 al features were sensitive symptoms (ataxia, paresthesia, hypoesthesia; n = 45, 100%), motor weakness

66 re detailed history revealed a gait problem, paresthesia in both feet, and nocturnal urinary frequenc

67 r, and speech abnormalities, with persistent paresthesias in four patients.

68 8% of the patients), dysgeusia (in 50%), and paresthesia (in 30%), and 3% discontinued repotrectinib

69 We show that paresthesia is absent not because axons do not spike but

70 al anesthesia/analgesia range from transient paresthesias (<10%) to potentially devastating epidural

71 ommon conditions and can result in numbness, paresthesia, motor deficits, and pain.

72 ontinuing topiramate were headache (N=3) and paresthesias (N=2).

73 the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication.

74 frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck

75 Self-resolving perineal abrasion and focal paresthesia of the glans penis each occurred in one pati

76 n day 4 she developed oral mucosal symptoms (paresthesia of the tongue, sore and an itchy throat).

77 fifty-three (76.5%) patients had numbness or paresthesias of the medial arm and/or axilla after surge

78 The neurologic examination showed paresthesias on the posterior aspect of both thighs and

79 euromuscular excitation resulting in tetany, paresthesia or seizure.

80 She did not report paresthesias or blue discoloration of her fingers when t

81 sinophilia, particularly in association with paresthesias or hyperesthesias, should alert clinicians

82 ealed uneventfully without wound dehiscence, paresthesia, or lip droop.

83 (P <or= .0016), seromas (P <or= .0001), and paresthesias (P <or= .0001) than those in the SLND-alone

84 amplitude corresponding to 50% to 70% of the paresthesia perception threshold.

85 , which in turn accurately predicts clinical paresthesia perception thresholds.

86 or no diagnostic value, including nocturnal paresthesias; Phalen and Tinel signs; thenar atrophy; an

87 notypes (typical GSS, GSS with areflexia and paresthesia, pure dementia GSS, and Creutzfeldt-Jakob di

88 e fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; w

89 dysgeusia (RR, 0.42; 95% CI, 0.21-0.85), and paresthesia (RR, 0.29; 95% CI, 0.13-0.67) were significa

90 tient satisfaction level were discomfort and paresthesia, satisfaction with appearance, and ability t

91 Axillary paresthesia, seroma, and impaired extremity range of mot

92 tients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor appetite and concentra

93 tients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor appetite, and concentr

94 Paresthesia symptoms were reported in 6 patients (3.2%,

95 piramate was associated with higher rates of paresthesia, taste perversion, confusion, and concentrat

96 tallic taste, visual disturbance, circumoral paresthesia, temperature reversal, or toothache) or syst

97 more wound infections, axillary seromas, and paresthesias than SLND alone.

98 and molecular mechanisms underlying tingling paresthesia that accompanies peripheral neuropathy and i

99 we paired biophysical modeling with clinical paresthesia thresholds (of both sexes) to investigate ho

100 igilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-

101 report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barre syndrome (GBS) oc

102 The ongoing debate regarding the use of paresthesia versus nerve-stimulator techniques is examin

103 Measurements and Main Results: Intermittent paresthesia was reported by 79%, 67%, and 18% of patient

104 ted in both treatment groups, but tremor and paresthesia were more frequent in the tacrolimus group.

105 ation, neutropenia, febrile neutropenia, and paresthesias were DLTs.

106 rointestinal toxicity, thrombocytopenia, and paresthesias) were all transient.

107 an increased incidence of hypertrichosis and paresthesia, were observed in the patients treated with

108 ) presented with episodic diplopia or facial paresthesias with subsequent brainstem and occasionally

109 latal and pharyngeal reflexes on both sides, paresthesia within the left half of the body.

110 of wobbly gait and bilateral lower extremity paresthesia without confusion.

111 of wobbly gait and bilateral lower extremity paresthesia without confusion.